Pranlukast Explained

Watchedfields:changed
Verifiedrevid:464213227
Iupac Name:N-[4-oxo-2-(1''H''-tetrazol-5-yl)-4''H''-chromen-8-yl]-4-(4-phenylbutoxy)benzamide
Tradename:Onon (オノン)
Routes Of Administration:Oral
Metabolism:Hepatic (mainly CYP3A4)[1]
Elimination Half-Life:1.5 hours
Iuphar Ligand:3634
Cas Number:103177-37-3
Atc Prefix:R03
Atc Suffix:DC02
Pubchem:4887
Drugbank:DB01411
Chemspiderid:4718
Unii:TB8Z891092
Chembl:21333
C:27
H:23
N:5
O:4
Smiles:O=C(Nc2cccc3c(=O)cc(c1nn[nH]n1)oc23)c5ccc(OCCCCc4ccccc4)cc5
Stdinchi:1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32)
Stdinchikey:NBQKINXMPLXUET-UHFFFAOYSA-N

Pranlukast (brand name Onon, オノン) is a cysteinyl leukotriene receptor-1 antagonist. This drug works similarly to Merck & Co.'s montelukast (Singulair). It is widely used in Japan.

Medications of this class, which go under a variety of names according to whether one looks at the American, British or European system of nomenclature, have as their primary function the antagonism of bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.[2]

Medications of this group are normally used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists. There are several similar medications in the group; all appear to be equally effective. Pranlukast is also reported as potential inhibitor of Mycobacterium tuberculosis infection in experimental models.[3]

Notes and References

  1. Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y, Yukawa E, Higuchi S . Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma . Drug Metabolism and Pharmacokinetics . 21 . 2 . 133–139 . April 2006 . 16702733 . 10.2133/dmpk.21.133 . dead . https://web.archive.org/web/20080917120315/http://www.jstage.jst.go.jp/article/dmpk/21/2/21_133/_article . 2008-09-17 .
  2. Singh RK, Tandon R, Dastidar SG, Ray A . A review on leukotrienes and their receptors with reference to asthma . The Journal of Asthma . 50 . 9 . 922–931 . November 2013 . 23859232 . 10.3109/02770903.2013.823447 . 11433313 .
  3. Mishra A, Mamidi AS, Rajmani RS, Ray A, Roy R, Surolia A . An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: Implications to a novel combinatorial therapy . EMBO Molecular Medicine . 10 . 4 . e8038 . April 2018 . 29483133 . 5887547 . 10.15252/emmm.201708038 .